Operating Segments (Tables)

9 Months Ended

Sep. 30, 2018

Operating Segments [Abstract]

Summary of operating segments

	Three Months Ended September 30,
	2018			2017
Contract/Grant Revenue
Vaccines/BioDefense	$	1,101,222		$	1,395,234
BioTherapeutics		280,131			426,832
Total	$	1,381,353		$	1,822,066
Income (Loss) from Operations
Vaccines/BioDefense	$	(29,743	)	$	48,840
BioTherapeutics		(1,066,152	)		(161,463	)
Corporate		(822,694	)		(857,000	)
Total	$	(1,918,589	)	$	(969,623	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	4,496		$	9,279
BioTherapeutics		5,247			7,792
Corporate		1,265			905
Total	$	11,008		$	17,976
Other Income (Expense), Net
Corporate	$	56,981		$	6,529
Share-Based Compensation
Vaccines/BioDefense	$	12,818		$	11,303
BioTherapeutics		28,109			22,827
Corporate		23,142			53,952
Total	$	64,069		$	88,082

	Nine Months Ended September 30,
	2018			2017
Contract/Grant Revenue
Vaccines/BioDefense	$	3,359,521		$	3,717,089
BioTherapeutics		867,149			426,832
Total		4,226,670		$	4,143,921
Income (Loss) from Operations
Vaccines/BioDefense	$	(85,649	)	$	382,710
BioTherapeutics		(3,511,460	)		(2,763,279	)
Corporate		(2,304,871	)		(2,644,073	)
Total	$	(5,901,980	)	$	(5,024,642	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	13,488		$	28,659
BioTherapeutics		15,976			25,436
Corporate		3,928			3,552
Total	$	33,392		$	57,647
Other Income, Net
Corporate	$	106,824		$	16,513
Share-Based Compensation
Vaccines/BioDefense	$	41,304		$	44,274
BioTherapeutics		78,325			95,424
Corporate		142,835			189,058
Total	$	262,464		$	328,756

	As of September 30, 2018		As of December 31, 2017
Identifiable Assets
Vaccines/BioDefense	$	956,638	$	906,416
BioTherapeutics		111,342		116,344
Corporate		12,221,409		8,526,891
Total	$	13,289,389	$	9,549,651